Introduction

In a pharmaceutical patent battle that spanned more than four years, Bayer AG’s infringement action against generic drug maker Lupin Limited over the blockbuster anticoagulant XARELTO® (rivaroxaban) concluded with a stipulated dismissal with prejudice in the Delaware District Court. Case No. 1:21-md-03017, filed December 10, 2021, and closed January 28, 2026, reflects the increasingly common resolution pathway in ANDA-related pharmaceutical patent litigation — negotiated exits that avoid full trial adjudication.

The case centered on U.S. Patent No. 10,828,310 B2, covering formulation or method-of-use claims tied to one of the world’s highest-grossing anticoagulant medications. For patent attorneys, IP professionals, and R&D leaders operating in the pharmaceutical space, the resolution of this multi-defendant litigation provides critical intelligence on litigation strategy, portfolio management, and the commercial calculus behind dismissals with prejudice in Hatch-Waxman disputes.

Aperçu du dossier

Les parties

Le brevet en cause

This litigation involved U.S. Patent No. 10,828,310 B2, tied to the blockbuster anticoagulant XARELTO® (rivaroxaban). Patents in the XARELTO® portfolio generally cover pharmaceutical compositions, dosage formulations, and methods of treatment using rivaroxaban. You can reference the full claim set via the USPTO Patent Full-Text Database.

Le produit incriminé

The accused product is XARELTO® (rivaroxaban), Bayer and Janssen’s co-commercialized oral anticoagulant. Lupin’s ANDA filing — seeking FDA approval for a generic rivaroxaban equivalent — constituted the act of alleged infringement under 35 U.S.C. § 271(e)(2).

Représentation juridique

Plaintiff’s Counsel: Bayer was represented by a formidable legal team spanning three prominent firms: Morris, Nichols, Arsht & Tunnell LLP, Williams & Connolly LLP – Washington, and Robinson Miller LLC. Key attorneys included Jack B. Blumenfeld and Derek James Fahnestock (Morris Nichols), and Bruce R. Genderson and Dov P. Grossman (Williams & Connolly).

Defendant’s Counsel: Lupin was represented by Phillips, McLaughlin & Hall PA, with attorneys Deepro R. Mukerjee, Lance A. Soderstrom, and Jitty Malik, Ph.D. leading the defense.

Chronologie du litige et historique de la procédure

The case was filed in the District of Delaware, the nation’s preeminent venue for pharmaceutical patent litigation. The multi-district litigation (MDL) designation indicates this action was consolidated with related ANDA challenges from multiple generic filers against the same XARELTO® patent(s).

The 1,510-day duration is consistent with complex pharmaceutical patent MDL proceedings, which routinely involve extensive claim construction briefing, expert discovery on validity and infringement, and sequential or staggered trial scheduling. The case closed without a district court merits ruling, indicating resolution through negotiated dismissal rather than judicial determination.

Le verdict et l'analyse juridique

Résultat

The litigation concluded via stipulated dismissal with prejudice pursuant to Federal Rules of Civil Procedure 41(a)(1) and 41(c). The dismissal covered all claims and defenses asserted by both Plaintiffs (Bayer Intellectual Property GmbH, Bayer AG, and Janssen Pharmaceuticals, Inc.) and Defendant Mankind Pharma Ltd. — notably identified in the dismissal order as the resolving defendant.

Each party bears its own costs, disbursements, and attorneys’ fees — a standard term in negotiated pharmaceutical patent settlements that eliminates post-litigation fee exposure for both sides.

Note: Specific financial settlement terms, royalty arrangements, or authorized generic agreements, if any, were not disclosed in the public record.

Analyse des causes du verdict

The action was classified as a straightforward infringement action under the Hatch-Waxman framework. No merits rulings — including claim construction orders, summary judgment decisions, or trial findings on validity or infringement — are reflected in the available case data, consistent with a pre-trial resolution.

The dismissal with prejudice is legally significant: it bars Bayer from re-filing infringement claims against Mankind Pharma on the same patent for the same ANDA product. Conversely, Mankind’s invalidity counterclaims — a routine component of ANDA defendant strategy — are also extinguished, preserving the patent’s validity record from adverse judicial findings.

Signification juridique

In Hatch-Waxman litigation, dismissals with prejudice typically signal one of several strategic outcomes:

• A **confidential settlement agreement** granting the generic an authorized entry date (potentially a negotiated launch date post-expiration or earlier under license)
• An **authorized generic arrangement** providing the ANDA filer a commercial pathway
• A determination by the generic challenger that litigation risk outweighed the commercial opportunity

The preservation of patent validity — with no court invalidating US-10828310-B2 — is a meaningful win for Bayer’s broader XARELTO® patent portfolio defense across remaining ANDA challengers.

Points stratégiques à retenir

For Patent Holders: Bayer’s litigation strategy — filing promptly upon ANDA notification, leveraging MDL consolidation, and engaging elite Delaware and D.C. counsel — reflects best-practice pharmaceutical patent enforcement. The dismissal-with-prejudice outcome preserves patent integrity while potentially securing favorable entry-date terms through settlement.

For Accused Infringers: Generic manufacturers should carefully assess commercial viability of ANDA challenges against deeply-resourced innovators with broad patent portfolios. A 1,510-day litigation timeline carries substantial legal cost exposure that must be weighed against the market opportunity of early generic entry.

For R&D Teams: Freedom-to-operate (FTO) analyses for rivaroxaban formulations must account for US-10828310-B2, which survives this litigation without invalidity findings. R&D teams developing competing anticoagulant formulations should conduct targeted claim mapping before product development investment.

Implications pour l'industrie et la concurrence

The XARELTO® MDL litigation reflects the broader pharmaceutical industry dynamic in which blockbuster small-molecule drugs face coordinated ANDA challenges from multiple generics simultaneously — a predictable consequence of the Hatch-Waxman paragraph IV certification incentive structure.

For the anticoagulant market, XARELTO®’s ongoing patent protection — reinforced by the absence of adverse validity rulings in this case — sustains Bayer and Janssen’s premium pricing position. Each dismissed or settled ANDA challenge without an invalidity finding strengthens the deterrent effect against future challengers.

The case also underscores Delaware’s continued dominance as the preferred pharmaceutical patent litigation venue. IP counsel advising branded pharmaceutical clients on venue strategy should note the court’s efficiency with MDL management and its deep institutional knowledge of Hatch-Waxman procedures.

For licensing professionals, the confidential settlement terms — whatever they may be — likely reflect market realities around rivaroxaban’s remaining patent life and the competitive entry timeline of other generic challengers who may have secured earlier authorized launch dates.